Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
I'm LongbridgeAI, I can summarize articles.
Bausch + Lomb reported first-quarter 2026 revenue of $1.244 billion, a 9% increase from the previous year. The company raised its full-year guidance based on strong performance, including double-digit growth in its Pharmaceuticals segment, driven by MIEBO and XIIDRA. Despite a GAAP net loss of $71 million, adjusted EBITDA reached $189 million. Key highlights include successful product launches and advancements in R&D, with a focus on operational efficiencies through AI adoption.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments